New allergy pill shows promise in ragweed season trial
NCT ID NCT06922448
First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times
Summary
This study tested a new drug called BLU-808 in 21 adults with ragweed allergies. The goal was to see if it is safe and helps reduce sneezing, runny nose, and itchy eyes caused by ragweed pollen. Participants were exposed to ragweed in a special chamber to measure the drug's effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
21 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria 1. Adults, 18 years of age or older, willing to provide written informed consent, and willing to comply with all study requirements. 2. History (\>2 years) of ragweed-induced ARC. 3. A positive ragweed skin prick test (mean diameter of ≥ 5 mm) in the last 6 months. 4. Must meet clinically relevant nasal and ocular symptoms as defined by the protocol. Key Exclusion Criteria Participants are excluded from the study if any of the following criteria are met: 1. Receiving medications (oral, nasal, topical, ocular, or injectable) to treat their ragweed or other allergy symptoms and/or receiving any medications that impact participants' safety or interfere with study assessments or interpretation of study results. 2. Have active rhinitis, sinusitis, and/or other severe allergies not associated with the ragweed pollen that may interfere with study symptom assessments. 3. Any prior or ongoing clinically significant illness, medical or psychiatric condition, surgical history, or physical finding that may interfere with the assessment or interpretation of study results. 4. Clinically significant moderate to severe, uncontrolled cardiovascular, renal or hepatic disease. 5. Significant bleeding risk or coagulation disorders. 6. Any form of smoking, vaping or history of alcohol and drug abuse. 7. Any malignancy within the past 5 years prior to Screening/AEC 1, except for basal cell or squamous cell carcinomas of the skin or carcinoma in situ. 8. Inadequately controlled asthma that could affect the safety of the participant or interfere with the assessment or interpretation of study results. 9. Known active/latent infection (viral, bacterial, fungal, helminth, or mycobacterial) such as tuberculosis, hepatitis B, hepatitis C, AIDS-related illness, or COVID-19 infection. 10. History of sinonasal conditions that may confound the assessment or interpretation of study results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic rhinoconjunctivitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Red Maple Trials
Ottawa, ON K1H E4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.